Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hoth Therapeutics, Inc. (HOTH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Hoth uses forms such as 10-K, 10-Q, 8-K, and registration statements to report on its business, financial condition, and material events.
In its Form 8-K filings, Hoth has reported items such as corporate presentations, employment agreements with key executives, patent-related developments for HT-001, and listing-compliance matters with The Nasdaq Capital Market. These current reports can give investors insight into topics like executive compensation arrangements, intellectual property strategy, and communications the company uses in discussions with investors.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically include detailed descriptions of Hoth’s pipeline programs, risk factors, research and development expenses, and other information relevant to its operations as a clinical-stage biopharmaceutical company. For Hoth, this may encompass narrative and disclosures related to HT-001, HT-KIT, HT-ALZ, its GDNF-based metabolic program, and other assets described in its public communications.
Stock Titan enhances access to these filings with AI-powered summaries that are designed to highlight key points from lengthy documents, such as major pipeline updates, regulatory milestones, or changes in capital structure. Users can review real-time updates as new filings are posted to EDGAR, explore Form 4 insider transaction reports when filed, and quickly navigate to sections that discuss clinical development, intellectual property, and corporate governance.
By using this page, investors and researchers can examine HOTH’s SEC filings alongside AI-generated explanations that aim to clarify complex language and help identify significant disclosures without replacing the need to read the original documents.
Hoth Therapeutics, Inc. filed a Form 8-K to inform the market that it has prepared new presentation materials that management plans to use on and after January 16, 2026. These materials are intended for meetings with U.S. government officials focused on the company’s weight loss drug and broader therapeutics pipeline.
The presentation materials are provided as Exhibit 99.1. Hoth notes that the information in these materials is summary in nature and should be read together with its other SEC filings and public announcements. The company states that the materials speak as of the date of this Form 8-K and, while it may update them in the future, it specifically disclaims any obligation to do so.
Hoth Therapeutics, Inc. has filed a mixed shelf registration statement on Form S-3 covering the primary offering of up to $50 million of common stock, preferred stock, debt securities, warrants, subscription rights and units, plus the resale of up to 1,279,587 shares of common stock by a selling shareholder. The company can issue these securities from time to time using a base prospectus and detailed prospectus supplements that will set terms such as pricing, ranking and any conversion features. As of November 10, 2025, Hoth had 15,514,312 shares of common stock outstanding, and it qualifies as a smaller reporting company, which allows scaled disclosure. The filing explains Hoth’s clinical‑stage pipeline in oncology side‑effect management, mast‑cell cancers, anaphylaxis, Alzheimer’s and other indications, along with extensive risk factors related to funding needs, clinical development, regulation, digital assets holdings and Nasdaq listing.
Hoth Therapeutics amended its prospectus supplement to expand its at-the-market program with H.C. Wainwright. The company is now offering up to $4,821,200 of common stock under the existing ATM agreement, after effectiveness and pursuant to General Instruction I.B.6 of Form S-3.
Since launching the ATM, Hoth has sold 3,919,559 shares for gross proceeds of about $5.5 million. The company cites a public float of approximately $30,968,682, which caps primary offerings at one-third of float over any 12-month period; the new $4,821,200 capacity reflects that limit. Shares trade on Nasdaq as “HOTH,” with a last reported sale price of $1.28 on November 12, 2025.
Hoth Therapeutics (HOTH) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $4.11 million for the quarter as operating expenses reached $4.08 million. For the nine months, the company recorded a net loss of $9.78 million.
Liquidity remained stable with cash and cash equivalents of $7.85 million as of September 30, 2025. Year‑to‑date, the company used $7.65 million in operating cash and received $8.76 million from financing, including warrant exercises and equity sales. Management states current cash is sufficient to fund operations for at least 12 months from the issuance date of these financial statements, while noting additional capital will be needed to advance programs.
The company maintained an ATM program with total capacity of $7.7 million; approximately $5.5 million of common stock had been sold under the program as of November 11, 2025. Shares outstanding were 15,514,312 as of November 11, 2025. Hoth also reported crypto assets at fair value of $274,695 (BTC, ETH, SOL). Equity activity included the CEO’s 800,000-share restricted stock grant in August.
Hoth Therapeutics (HOTH) filed a Form 8-K to announce that management has prepared investor presentation materials for use on and after October 17, 2025. The materials are included as Exhibit 99.1 and provide summary information about the company’s operations and performance.
The presentation speaks as of the 8-K date, and the company notes it may update the materials but disclaims any obligation to do so. No transactions, financial results, or new guidance are disclosed in this filing.
Robb Knie, CEO and President and a director of Hoth Therapeutics, acquired 800,000 shares of restricted common stock under the company’s Amended and Restated 2022 Equity Incentive Plan; the award vested in full at grant and was issued at $0 per share, bringing his post-award beneficial ownership to 858,131 shares. The next day he sold 310,744 shares at $1.21 per share, reducing his beneficial ownership to 547,387 shares. The Form 4 shows the acquisition was labeled as an issuance that vested on grant and the sale was reported separately. The filing was signed by an attorney-in-fact on behalf of Mr. Knie.
Hoth Therapeutics, Inc. disclosed a material agreement: an Employment Agreement between the company and Robb Knie dated
Hoth Therapeutics, Inc. reported $9.0 million in cash and cash equivalents at June 30, 2025, up from $7.0 million at year-end 2024, and total assets of $10.1 million. The company recorded a six-month net loss of $5.68 million versus $3.86 million in the prior-year period, driven in part by a $1.25 million immediate expensing of acquired patent applications and higher research and development spending. Weighted average shares increased materially, lowering six-month loss per share to $0.44 from $0.68 a year earlier despite a larger absolute loss.
Operating cash used was $5.16 million for the six months, while financing activities provided $7.13 million, including $5.625 million from warrant exercises. Management states current cash is sufficient to fund operations for at least 12 months from issuance, but additional capital will be required for longer-term development and regulatory plans. The company continues clinical and preclinical programs across multiple candidates and maintains an ATM facility with selling capacity expanded to $7.7 million.
Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.
Key points from the filing:
- The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
- The company maintains discretion to update the materials but has no obligation to do so
- Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
- The information will not be incorporated by reference into any Securities Act or Exchange Act filings
The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
